“Not for Human Consumption”: A Review of Emerging Designer Drugs
Megan E. Musselman, Jeremy P. Hampton
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy April 8, 2014 DOI: 10.1002/phar.1424 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Citations | 85 |
| Key findings | The authors argue that designer drugs, which mimic hallucinogens, stimulants, or opioids and are deceptively marketed, pose growing and difficult-to-manage toxicity risks because their contents and potency cannot be verified; they contend that clinicians need thorough knowledge of these agents, their toxicity signs, and potential treatments to manage patients appropriately. |
Abstract
Synthetic, or "designer" drugs, are created by manipulating the chemical structures of other psychoactive drugs so that the resulting product is structurally similar but not identical to illegal psychoactive drugs. Originally developed in the 1960s as a way to evade existing drug laws, the use of designer drugs has increased dramatically over the past few years. These drugs are deceptively packaged as "research chemicals," "incense," "bath salts," or "plant food," among other names, with labels that may contain warnings such as "not for human consumption" or "not for sale to minors." The clinical effects of most new designer drugs can be described as either hallucinogenic, stimulant, or opioid-like. They may also have a combination of these effects due to designer side-chain substitutions. The easy accessibility and rapid emergence of new designer drugs have created challenges for health care providers when treating patients presenting with acute toxicity from these substances, many of which can produce significant and/or life-threatening adverse effects. Moreover, the health care provider has no way to verify the contents and/or potency of the agent ingested because it can vary between packages and distributors. Therefore, a thorough knowledge of the available designer drugs, common signs and symptoms of toxicity associated with these agents, and potential effective treatment modalities are essential to appropriately manage these patients.
Citations in the library
Cited by 12
- The hallucinogenic world of tryptamines: an updated review. Archives of Toxicology August 1, 2015
- Recreational Use, Analysis and Toxicity of Tryptamines Current Neuropharmacology December 10, 2014
- Trends in DMT and other tryptamine use among young adults in the United States American Journal on Addictions September 27, 2018
- Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties Molecular Psychiatry March 14, 2024
- Substance Use and Attendance Motives of Electronic Dance Music (EDM) Event Attendees: A Survey Study International Journal of Environmental Research and Public Health January 19, 2023
and 7 more in the library
Cites 12
- Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. Journal of Medical Toxicology March 1, 2012
- “Spiceophrenia”: a systematic overview of “Spice”‐related psychopathological issues and a case report Human Psychopharmacology: Clinical and Experimental July 1, 2013
- 2,5-Dimethoxy-4-methyl-amphetamine (STP): A New Hallucinogenic Drug Science November 3, 1967
- 25C-NBOMe--new potent hallucinogenic substance identified on the drug market. Forensic Science International April 10, 2013
- Metabolism of designer drugs of abuse: an updated review. Current Drug Metabolism June 1, 2010
and 7 more in the library